5.235USD-1.97%Mkt Cap: 132.67M USDP/E: —Last update: 2026-05-26
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap132.67M USD
Enterprise Value139.64M USD
Revenue (TTM)0 USD
Gross Profit0 USD
Net Income (TTM)-62.15M USD
Revenue/Share0.0000 USD
Last Price5.235 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.38
PEG—
EV/EBITDA—
EV/Revenue—
P/SInfinity
P/B-6.73
EPS (TTM)-1.80
EPS (Forward)-0.64
52W Range
3.20021% of range12.99
52W High12.99 USD
52W Low3.200 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-155404.38%
ROE354.96%
ROA-2200.93%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-20.36M USD
CapEx (TTM)500.00K USD
FCF Margin—
FCF Yield-1.21%
Net Debt207.45K USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.36
Current Ratio0.13
Quick Ratio0.01
Book Value/Sh-0.7960 USD
Cash/Share0.0050 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)16.00 USD
Target Range13.00 USD – 20.00 USD
# Analysts3
Ownership
Shares Out.26.01M
Float8.12M
Insiders56.04%
Institutions11.25%
Short Interest
Short Ratio4.3d
Short % Float1.80%
Short % Out.1.09%
Shares Short274.80K
Short (prev mo.)289.78K
Technical
SMA 505.952 (-12.0%)
SMA 2008.244 (-36.5%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)90.16K
Avg Vol (10d)82.78K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—